For overpricing bone marrow cancer drug The Competition Commission has referred for prosecution to the Competition Tribunal (“Tribunal”), international drug manufacturer Celgene Corporation (“Celgene Corp”) and its subsidiary Celgene Logistics S.a.r.l (“Celgene Logistics”) (collectively, “Celgene”). The companies are alleged to have contravened the Competition Act 89 of 1998, as amended, by the alleged excessive pricing of a bone marrow cancer treatment drug, Revlimid. Revlimid (Lenalidomide)...